<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01004744</url>
  </required_header>
  <id_info>
    <org_study_id>AAAC0553</org_study_id>
    <nct_id>NCT01004744</nct_id>
  </id_info>
  <brief_title>Pre-Surgical Intervention for Targeted Therapies for Breast Cancer</brief_title>
  <official_title>Feasibility of Pre-Surgical Intervention Studies for Evaluating Targeted Therapies for Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Avon Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the feasibility of a short term administration of a&#xD;
      targeted therapy (i.e., anastrozole) in women with newly diagnosed early invasive or non&#xD;
      invasive breast cancer during the interval between their breast biopsy and surgery.&#xD;
      Anastrozole is a form of hormonal therapy which is part of the standard treatment for hormone&#xD;
      sensitive breast cancer in postmenopausal women. This clinical model is being used to&#xD;
      evaluate the biologic effects of this drug on a specific molecular pathway called the&#xD;
      PI3K/AKT signaling pathway.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Several clinical models are being explored for use in the phase I/II evaluation of targeted&#xD;
      therapies for breast cancer. Biological markers can be measured in early stage invasive&#xD;
      cancers in a presurgical model involving a short term intervention. In this model, women with&#xD;
      newly diagnosed early invasive breast cancer receive a study drug during the interval between&#xD;
      diagnostic breast biopsy and surgical resection. Tumor tissue obtained from the biopsy and&#xD;
      surgical specimens are used to measure pre and post treatment molecular markers,&#xD;
      respectively. The main advantages of this model include the ability to obtain direct&#xD;
      information on molecular response in tumor tissue and elucidate drug mechanisms of action,&#xD;
      the large patient population to draw from with early stage breast cancer, and the lack of&#xD;
      unnecessary invasive procedures.&#xD;
&#xD;
      We plan to conduct a pilot study of 10 postmenopausal women with newly diagnosed estrogen&#xD;
      receptor (ER) positive invasive or non invasive breast cancer who will receive oral&#xD;
      anastrozole 1mg daily for two weeks in the interval between diagnostic breast biopsy and&#xD;
      definitive breast surgery. Patients will be identified by the breast surgeon or mammographer&#xD;
      performing the breast biopsy. Patients with histologically confirmed ER+ invasive or non&#xD;
      invasive breast cancer will be recruited by the medical oncologist and will start anastrozole&#xD;
      two weeks prior to their scheduled surgery. The primary objective of this study is to&#xD;
      demonstrate the feasibility of this presurgical model for evaluating targeted therapies for&#xD;
      breast cancer. Secondary endpoints include changes in tissue levels of the proliferation&#xD;
      marker Ki67 and proteins involved in PI3K/AKT signaling.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects That Completed Oral Anastrozole 1mg Daily for Two Weeks in the Interval Between Diagnostic Breast Biopsy and Definitive Breast Surgery</measure>
    <time_frame>Two weeks</time_frame>
    <description>The number of subjects who complete oral anastrozole for the length of the study is analyzed. The subjects receive oral anastrozole 1mg daily for two weeks in the interval between the biopsy and the surgery.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Invasive Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Presurgical oral anastrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1mg daily for two weeks in the interval between diagnostic breast biopsy and definitive breast surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anastrozole</intervention_name>
    <description>1mg PO daily for two weeks prior to scheduled surgery</description>
    <arm_group_label>Presurgical oral anastrozole</arm_group_label>
    <other_name>Arimidex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically-confirmed operable ER+ and/or PR+ invasive breast cancer or ductal&#xD;
             carcinoma in situ (DCIS), who undergo core needle biopsy followed by surgical excision&#xD;
             at least 2 weeks after enrollment&#xD;
&#xD;
          -  Postmenopausal status defined as cessation of menses for &gt;1 year or FSH &gt; 20 mIU/mL&#xD;
             (within the past month)&#xD;
&#xD;
          -  Age â‰¥ 21 years&#xD;
&#xD;
          -  No prior chemotherapy, radiation therapy, or surgery within 6 months of study entry&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with other investigational drugs within 6 months of study entry&#xD;
&#xD;
          -  Other serious intercurrent medical illness&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Crew, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 28, 2009</study_first_submitted>
  <study_first_submitted_qc>October 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2009</study_first_posted>
  <results_first_submitted>July 27, 2015</results_first_submitted>
  <results_first_submitted_qc>January 7, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">January 11, 2021</results_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Katherine D. Crew</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine and Assistant Professor of Epidemiology</investigator_title>
  </responsible_party>
  <keyword>Postmenopausal women</keyword>
  <keyword>ER+</keyword>
  <keyword>Estrogen positive</keyword>
  <keyword>PR+</keyword>
  <keyword>Progesterone positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anastrozole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients will be identified by the breast surgeon or mammographer performing the breast biopsy. Patients with histologically-confirmed ER+ invasive or non-invasive breast cancer will be recruited by the medical oncologist and will start anastrozole two weeks prior to their scheduled surgery.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Presurgical Oral Anastrozole</title>
          <description>1mg daily for two weeks in the interval between diagnostic breast biopsy and definitive breast surgery.&#xD;
Anastrozole: 1mg PO daily for two weeks prior to scheduled surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Presurgical Oral Anastrozole</title>
          <description>1mg daily for two weeks in the interval between diagnostic breast biopsy and definitive breast surgery.&#xD;
Anastrozole: 1mg PO daily for two weeks prior to scheduled surgery</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" lower_limit="49" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects That Completed Oral Anastrozole 1mg Daily for Two Weeks in the Interval Between Diagnostic Breast Biopsy and Definitive Breast Surgery</title>
        <description>The number of subjects who complete oral anastrozole for the length of the study is analyzed. The subjects receive oral anastrozole 1mg daily for two weeks in the interval between the biopsy and the surgery.</description>
        <time_frame>Two weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Presurgical Oral Anastrozole</title>
            <description>1mg daily for two weeks in the interval between diagnostic breast biopsy and definitive breast surgery.&#xD;
Anastrozole: 1mg PO daily for two weeks prior to scheduled surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects That Completed Oral Anastrozole 1mg Daily for Two Weeks in the Interval Between Diagnostic Breast Biopsy and Definitive Breast Surgery</title>
          <description>The number of subjects who complete oral anastrozole for the length of the study is analyzed. The subjects receive oral anastrozole 1mg daily for two weeks in the interval between the biopsy and the surgery.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Presurgical Oral Anastrozole</title>
          <description>1mg daily for two weeks in the interval between diagnostic breast biopsy and definitive breast surgery.&#xD;
Anastrozole: 1mg PO daily for two weeks prior to scheduled surgery</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Katherine Crew</name_or_title>
      <organization>Columbia University</organization>
      <phone>212-305-1732</phone>
      <email>kd59@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

